Back to top
more

Chemed (CHE)

(Real Time Quote from BATS)

$562.79 USD

562.79
34,376

+4.52 (0.81%)

Updated Nov 11, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms Guidance

by Zacks Equity Research

Strength in the VITAS and Roto-Rooter branches contributes to Chemed's (CHE) first-quarter top line.

CONMED (CNMD) Beats on Q1 Earnings, Ups '23 EPS View

by Zacks Equity Research

CONMED's (CNMD) adjusted first-quarter sales and earnings recover from the disruption in the fourth quarter due to implementation of a new warehouse management system.

Chemed (CHE) Q1 Earnings Lag Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of -2.03% and 2.56%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

EHC vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

EHC vs. CHE: Which Stock Is the Better Value Option?

Here's Why Investors Should Hold Ensign Group (ENSG) Stock Now

by Zacks Equity Research

Ensign Group (ENSG) remains well-poised for growth on the back of a growing revenue base, continuous pursuit of acquisitions and commendable financial position.

PNTG vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PNTG vs. CHE: Which Stock Is the Better Value Option?

Zacks Industry Outlook Highlights Chemed, Addus HomeCare, RadNet and The Pennant Group

by Zacks Equity Research

Chemed, Addus HomeCare, RadNet and The Pennant Group are part of the Zacks Industry Outlook article.

Debanjana Dey headshot

4 Promising Stocks From a Challenging Outpatient Home Health Industry

by Debanjana Dey

Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. CHE, ADUS, RDNT and PNTG are well poised to gain from the prospects.

Chemed (CHE) Up on Roto-Rooter Sales Growth, Strong Admissions

by Zacks Equity Research

Chemed (CHE) records increases in drain cleaning, plumbing, excavation and water restoration revenues within the Roto-Rooter branch commercial business.

Is Bellicum Pharmaceuticals (BLCM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bellicum Pharmaceuticals (BLCM) and Chemed (CHE) have performed compared to their sector so far this year.

PNTG or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PNTG vs. CHE: Which Stock Is the Better Value Option?

PNTG vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

PNTG vs. CHE: Which Stock Is the Better Value Option?

Chemed (CHE) Q4 Earnings Beat Estimates, Margins Contract

by Zacks Equity Research

Chemed (CHE) reports impressive sales growth in the Roto-Rooter subsidiary in the fourth quarter of 2022.

Chemed (CHE) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 1.70% and 0.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

DaVita HealthCare (DVA) Q4 Earnings Beat Estimates

by Zacks Equity Research

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 26.14% and 0.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

PNTG or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PNTG vs. CHE: Which Stock Is the Better Value Option?

PNTG vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

PNTG vs. CHE: Which Stock Is the Better Value Option?

Chemed (CHE) Q3 Earnings Surpass Estimates, EPS View Up

by Zacks Equity Research

Chemed's (CHE) full-year VITAS revenues, prior to Medicare Cap, are once again estimated to decline.

Chemed (CHE) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 2.82% and 1.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Chemed (CHE) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Chemed (CHE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Earnings Preview: Chemed (CHE) Q3 Earnings Expected to Decline

by Zacks Equity Research

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Chemed (CHE) Stock?

by Zacks Equity Research

Investors need to pay close attention to Chemed (CHE) stock based on the movements in the options market lately.

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Chemed's (CHE) Roto-Rooter business, which is witnessing continued demand for plumbing, drain cleaning services and water restoration services.

    Option Care (OPCH) Stock Jumps 8.9%: Will It Continue to Soar?

    by Zacks Equity Research

    Option Care (OPCH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

    Chemed (CHE) Roto-Rooter Business Grows, VITAS Admission Dips

    by Zacks Equity Research

    The performance of Chemed's (CHE) VITAS business is somewhat offset by a geographically weighted average Medicare reimbursement rate increase.